Rivastigmine in Alzheimer disease: Efficacy over two years

American Journal of Geriatric Psychiatry

Volumn 12, Issue 4, 2004, Pages 420-431

  Grossberg, George ^b   Irwin, Peter ^a   Satlin, Andrew ^a   Mesenbrink, Peter ^a   Spiegel, René ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

ABDOMINAL PAIN; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVALUATION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TASK PERFORMANCE; URINE INCONTINENCE; VOMITING; WEIGHT REDUCTION;

EID: 3042817491     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200407000-00010     Document Type: Article

References (32)

1. Cummings JL: Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157:4-15
2. Perry EK, Perry RH, Blessed G, et al: Changes in brain cholinesterases in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 1978; 4:273-277
3. Smith MA: Alzheimer Disease. Int Rev Neurobiol 1998; 42:1-54
4. Enz A, Amstutz R, Boddeke H, et al: Brain-selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993; 98:431-438
5. Giacobini E: Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 2001; 15:85-91
6. Schneider LS: The future of cholinergic replacement therapy in Alzheimer's disease. Curr Opin CNS Investigational Drugs 2000; 2:427-437
7. VanDenBerg ChM, Kazmi Y, Jann MW: Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. Drugs Aging 2000; 16:123-138
8. Davis KL, Mohs RC, Marin D, et al: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 15:1401-1406
9. Mohs RC, Doody RS, Morris JC, et al: A 1-year, placebo-controlled preservation-of-function survival study of donepezil in AD patients. Neurology 2001; 57:481-488
10. Winblad B, Engedal K, Soininen H, et al: A one-year, randomized, placebo-controlled study of donepezil in patients with mild-to-moderate AD. Neurology 2001; 57:489-495
11. Miguel-Hidalgo JJ: Rivastigmine. Current Opinion in CNS Investigational Drugs 2000; 2:438-453
12. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1:55-65
13. Rösler M, Anand R, Cicin-Sain A, and the B303 Exelon Study Group, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318:633-640
14. Doody RS, Dunn JK, Clark CM, et al: Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 12:295-300
15. Rogers SL, Doody RS, Pratt RD, et al: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a U.S. multicentre open-label study. Eur Neuropsychopharmacol 2000; 10:195-203
16. Doody RS, Geldmacher DS, Gordon B, et al: Open-label, multicenter Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58:427-433
17. Farlow M, Anand R, Messina J, et al: A 52-week study of the efficacy of rivastigmine in patients with mild-to-moderately severe Alzheimer's disease. Eur Neurol 2000; 44:236-241
18. Raskind MA, Peskind ER, Wessel T, et al: Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54:2261-2268
19. Anand R, Messina J, Hartman R: Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000; 2:68-72
20. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
21. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
22. Dejong R, Osterlund OW, Roy GW: Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1989; 11:545-554
23. Reisberg B, Schneider L, Doody R, et al: Clinical global measure of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11(suppl3):8-18
24. Leber P: Observations and suggestions on anti-dementia drug development. Alzheimer Dis Assoc Disord 1996; 10(suppl 1):31-35
25. Stern RG, Mohs RC, Davidson M, et al: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151:390-396
26. Mendiondo MS, Ashford JW, Kryscio RJ, et al: Modeling MiniMental State Exam changes in Alzheimer's disease. Statist Med 2000; 19:1607-1616
27. Thal LJ, Calvani M, Amato A, et al: A one-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology 2000; 55:805-810
28. Van Gool WA, Weinstein HC, Scheltens PhK, et al: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358:455-460
29. Han L, Cole M, Bellavance F, et al: Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Exam: a meta-analysis. Int Psychogeriatr 2000; 12:231-247
30. Olichney JM, Galasko D, Salmon DP, et al: Cognitive decline is faster in Lewy-body variant than in Alzheimer's disease. Neurology 1998; 51:351-357
31. Physicians' Desk Reference. Medical Economics Company, Inc., Montvale, NJ, 2001, (supplA):227-230
32. BMJ Editorial: Which clinical studies provide the best evidence? BMJ 2000; 321:255-256